NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

A brightly-lit, 10-story building off Interstate-40 in Durham is now the headquarters for the largest drug development service provider in the world. Quintiles officially dedicated the building on Page Road Thursday with a ceremony attended by hundreds, including Gov. Beverly Perdue and Durham Mayor Bill Bell.

Quintiles has promised to create 1,000 new jobs in North Carolina by 2012 in exchange for approximately $23 million in tax breaks and other incentives. More than 400 jobs have already been created.

E. Norris Tolson, president and CEO of the North Carolina Biotechnology Center, was appointed today by Gov. Bev Perdue to the North Carolina State University Board of Trustees.

"I am pleased to be asked to serve my university as a trustee," said Tolson, 69, who earned his bachelor's degree in crop science and agribusiness from the university. "NCSU has helped shape my life and I am delighted to give something back."

Cook Medical, a medical device company in Winston-Salem, has designed the first and only high-definition endoscopic ultrasound needle technology on the market. Cook's needles, which are up to three times brighter than others available, will allow physicians to provide potentially safer and more accurate diagnostic procedures.

Read the full press release

Patients with pulmonary aretery hypertension will have a new treatment as early as August.

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved ADCIRCA™. In clinical trials, patients who took the drug were able to exercise longer and their condition worsened less than the group than did not take the treatment.

This afternoon an agreement was signed to create the Hamner-China Medical City Institute for International Drug Development. A collaboration between the Hamner Institutes for Health Sciences and China Medical City, this partnership will enable both countries to more easily enter each other's markets.


Non-Hodgkin lymphoma is the fifth-leading cancer killer in humans - and is ranked even higher in the canine world. That's why North Carolina State University's College of Veterinary Medicine and the University of North Carolina's Lineberger Comprehensive Cancer Center are working together to determine the cause of and improve treatments for the disease in both humans and dogs.

Durham's Hyperbranch Medical Technology has raised $1.17 million in equity financing. The company's product, OcuSeal, is a liquid eye bandage that provides a temporary barrier after surgery or trauma to the eye. Becton, Dickinson & Co. plans to commercialize the product.


The Research Triangle Park-based Hamner Institutes for Health Sciences (The Hamner) took home multiple awards from the Society of Toxicology's 48th Annual Meeting and ToxExpo.


Russell Thomas, Ph.D., director of The Hamner Center for Genomic Biology and Bioinformatics, received the 2009 Achievement Award for his contributions in speeding up collection of detailed information about how chemicals cause toxicity in the body, which may reduce the need to use animals in testing.


Durham drug development firm Addrenex Pharmaceuticals has licensed a new drug from SK Life Science Business Division, the drug-discovery and development division of SK Holdings, one of the largest multinational companies based in South Korea.


The 3-year-old Addrenex was founded with the help of $160,000 in loans from the North Carolina Biotechnology Center.


Chapel Hill drug company POZEN said it has received the go-ahead from its collaborator, global pharmaceutical giant AstraZeneca, to file for marketing approval from federal regulators for PN 400, one of Pozen's experimental medicines.


PN 400 combines enteric-coated naproxen with esomeprazole to reduce the risk of gastric ulcers in treating arthritis.


Vipin Garg, Ph.D., president and CEO of Research Triangle Park-based Tranzyme Pharma and a member of the North Carolina Biotechnology Center board of directors, is a finalist for the Ernst & Young Entrepreneur Of The Year 2009 Award in the Carolinas.


The U.S. Food and Drug Administration has approved GlaxoSmithKline's marketing of Lamictal Orally Disintegrating Tablets to treat bipolar disorder and seizures.


British-based GSK's U.S. headquarters are in Research Triangle Park.


Marketed as Lamictal ODT, the new formulation uses a novel drug-delivery system to provide Lamictal in an easy-to-take tablet form that has a pleasant taste and disintegrates on the tongue.


Researchers at the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center have found a gene defect that may be a prime culprit in the development of most breast cancers.

Winston-Salem-based Targacept has announced positive preliminary results from a Phase II clinical trial involving its experimental compound AZD3480 in adults with attention deficit/hyperactivity disorder (ADHD).


The company targets its R&D effort on neuronal nicotinic receptors -- cellular machinery seen as a key to regulating various functions within the nervous system.